• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The WARSS trial: Warfarin vs aspirin in preventing recurrent ischemic stroke [Classics Series]

byAndrew Cheung, MD MBA
September 1, 2013
in General Medicine Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Warfarin is not superior to aspirin in preventing recurrent ischemic stroke in patients with a prior noncardioembolic ischemic stroke

2. There was no significant difference in the rates of major hemorrhage when comparing warfarin with aspirin

Original Date of Publication: November 15, 2001

Study Rundown: Previous studies had shown that warfarin was associated with lower rates of embolic stroke than aspirin in patients with atrial fibrillation. Additionally, while aspirin was the treatment of choice for the prevention of recurrent events in noncardioembolic ischemic strokes, a substantial rate of recurrence was observed clinically. The WARSS trial therefore sought to investigate whether warfarin may be superior to aspirin in the prevention of recurrent ischemic stroke in patients with prior noncardioembolic strokes.

The study showed no significant difference between warfarin and aspirin in the prevention of recurrent ischemic strokes. In other words, warfarin did not decrease the rate of recurrent stroke in patients with a prior noncardioembolic stroke, as it does for patients with atrial fibrillation. Because the WARSS study was only powered to detect a 30% relative reduction in primary outcome, it is possible that the study was underpowered to detect more modest treatment effects. Additionally, while there was no difference in rates of major hemorrhage (e.g., intracranial, intraspinal, dural/epidural bleeding) between aspirin and warfarin use, patients on warfarin had significantly more minor hemorrhages (e.g., gastrointestinal bleeding, ecchymoses).

In summary, the results of the WARSS trial suggest that aspirin is a reasonable choice for prophylaxis against recurrent noncardioembolic ischemic stroke, given that warfarin requires closer monitoring, without being more efficacious.

RELATED REPORTS

Improved mortality rates for myocardial infarction, stroke, and pulmonary embolism in patients receiving dialysis between 1998 to 2015

Reduced bleeding risk with asundexian compared to apixaban in patients with atrial fibrillation

Large vessel occlusion stroke is associated with poor prognosis in children

Please click to read study in NEJM

In-Depth [randomized, controlled study]: Published in NEJM in 2001, the WARSS trial was a randomized, double-blinded clinical trial conducted in 48 academic centers in the U.S. A total of 2,206 patients aged 30-85 with a noncardioembolic ischemic stroke within the previous 30 days and scores of 3 or more on the Glasgow Outcome Scale were randomized to receive warfarin (dosed to a target INR of 1.4-2.8) or aspirin (325 mg daily). The primary endpoint was death from any cause or recurrent ischemic stroke. Rates of major hemorrhage (e.g., intracranial, intraspinal) and minor hemorrhage (e.g., gastrointestinal, ecchymoses) were also recorded. There was no significant difference between the warfarin and aspirin groups in the time to the primary endpoint (HR 1.13; 95%CI 0.92-1.38). There was also no difference in the rates of major hemorrhage (P=0.10), though rates of minor hemorrhage were significantly higher in the warfarin group (P<0.001). Finally, there was no significant difference in time to the primary endpoint due to patient differences in gender, ethnicity, or subtype of prior stroke.

By Evan Chen and Andrew Cheung, M.D.

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain.

Tags: strokewarfarin
Previous Post

Fetal inflammatory response syndrome linked to poor neonatal outcomes

Next Post

Clinical prediction rule stratifies pediatric bacterial meningitis risk [Classics Series]

RelatedReports

Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Improved mortality rates for myocardial infarction, stroke, and pulmonary embolism in patients receiving dialysis between 1998 to 2015

April 22, 2022
Stroke expansion following intra-arterial therapy may explain worse outcomes
Cardiology

Reduced bleeding risk with asundexian compared to apixaban in patients with atrial fibrillation

April 19, 2022
Combined MRI and NIH stroke scores may predict stroke prognosis
Emergency

Large vessel occlusion stroke is associated with poor prognosis in children

March 29, 2022
Intensive rehabilitation not superior to traditional therapy for arm function after stroke
Cardiology

Increased risk of intracranial hemorrhage with aspirin and unfractionated heparin use for endovascular stroke treatment

March 22, 2022
Next Post
Classics Series, Landmark Trials in Medicine

Clinical prediction rule stratifies pediatric bacterial meningitis risk [Classics Series]

AAP recommendations for the upcoming 2013 – 2014 influenza season

AAP recommendations for the upcoming 2013 – 2014 influenza season

Adult decision rules poor proxy for diagnosing pediatric PE

Adult decision rules poor proxy for diagnosing pediatric PE

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine Rewind May 22nd, 2022
  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.